PPCB Company Profile and Key Details

Propanc Biopharma, Inc. generated EPS of -$13.54 over the past year. Five-year average earnings growth is 98.33%.

Propanc Biopharma, Inc. has 2.28 million shares outstanding. The public float is 1.25 million shares, elevated short interest at 0.99% of float. This equals 20.15 thousand shares. The short ratio is 0.01 days. Institutional investors hold 1.48% of the float. Insiders own 45.13%.

PPCB has shown weak momentum, losing -34.05% over the past week and -81.09% over the past quarter, though year-to-date performance is down -44.32%. Short-term trend indicators are bullishly aligned (SMA20 -7.56%, SMA50 -49.38%, SMA200 -92.23%). The stock’s 14-day RSI is 34.19 (weak momentum), while the ATR of 0.04 points to moderate volatility. The stock remains hovering near 52-week lows, trading -98.23% below its high and over 25.53% above its low. Average 10-day trading volume of 12.10 million shares is significantly above the 3-month average of 5.39 million, indicating heightened recent market interest.

Propanc Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.43. This means the shares are trading below this model’s fair value.

Propanc Biopharma, Inc. (NASDAQ:PPCB) closed at $2.23 USD, gaining $1.16 (108.41%) from the previous close of $1.07. The stock is currently mid-range between its 52-week high and low $0.95 and $81.00. With a market capitalization of about $5.08 million, Propanc Biopharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.27). Key stats such as the average daily volume over the past year has been around 5.40 million shares, trading with heavier-than-usual volume. Headquartered in Camberwell, VIC, Propanc Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James Nathanielsz, the company employs approximately 2 people and listed since November 12, 2012. Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies.

Propanc Biopharma, Inc. trades at a P/E ratio of -0.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.21 suggesting the stock is closer to book value. The P/FCF stands at -1.28, also above market averages.

Our AI price prediction model suggests that Propanc Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -28.7%, with price expected at $1.59 by September 10, 2026, within a range of $1.37 to $1.81 3-Month Outlook: Projected fall of -74.89%, reaching $0.56 by November 25, 2026, with a range of $0.40 to $0.72. 1-Year Outlook: Projected loss of -94.62%, with price at $0.12 by August 27, 2027, within a range of $0.00 to $0.26.

Propanc Biopharma, Inc. (NASDAQ:PPCB) shares are down -44.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Propanc Biopharma, Inc. trading at a premium to the broader market with a P/E of -0.07. Our AI forecast model points to short-term weakness (-28.7% over two weeks), a medium-term fall (-74.89% over three months), and a longer-term loss (-94.62% over one year), with expected trading ranges indicating moderate volatility.